Amphista Lands Megadeals to Smash Cancer using Protein Degradation
Amphista Lands Megadeals to Smash Cancer using Protein Degradation
5 May 2022
Labiotech.eu – View full story
Two Pharma Giants Link Up With Amphista on Protein Degradation Projects
Two Pharma Giants Link Up With Amphista on Protein Degradation Projects
5 May 2022
FDANews – View full story
Article requires subscription to view full text
Multi-billion dollar vote of confidence in UK protein specialist
Multi-billion dollar vote of confidence in UK protein specialist
5 May 2022
The Pharma Letter – View full story
Dundee’s Amphista strikes collaboration deals that could be worth billions
Dundee’s Amphista strikes collaboration deals that could be worth billions
5 May 2022
The Herald Scotland – View full story
Amphista Therapeutics signs with pharma on drug development projects
Amphista Therapeutics signs with pharma on drug development projects
5 May 2022
Drug Discovery World – View full story
Amphista Signs a License Agreement with BMS to Discover & Develop Targeted Protein Degradation Therapies Using Eclipsys TPD Platform
Amphista Signs a License Agreement with BMS to Discover & Develop Targeted Protein Degradation Therapies Using Eclipsys TPD Platform
5 May 2022
PharmaShots – View full story
Amphista Therapeutics to Collaborate with Merck for Discovery and Development of Targeted Protein Degradation Therapeutics
Amphista Therapeutics to Collaborate with Merck for Discovery and Development of Targeted Protein Degradation Therapeutics
4 May 2022
American Pharmaceutical Review – View full story
Amphista announces collaborations potentially worth $2 billion
Amphista announces collaborations potentially worth $2 billion
4 May 2022
Bio-dundee – View full story
BMS and Merck Buy Big Into Amphista’s Protein Degradation Platform
BMS and Merck Buy Big Into Amphista’s Protein Degradation Platform
4 May 2022
PharmaLive – View full story
Reprint of BioSpace article
Bristol Myers Squibb (BMY) Announces Amphista Therapeutics Collaboration
Bristol Myers Squibb (BMY) Announces Amphista Therapeutics Collaboration
4 May 2022
InvestorsObserver – View full story
